![]() Arguably 1985 was his best season as he won both the Overseas and Intercontinental Finals on his way to the World Final at Bradford. He rode in three World Championships in 1984 ( Göteborg) where he finished 8th, 1985 ( Bradford) where he finished 5th and 1990 (Bradford). Moran was first nicknamed 'Shooey' by Bobby "Boogaloo" Schwartz and it stuck throughout his career. Although regarded as a world-class rider, the individual World Championship eluded him. Shawn amassed a total of 3,257 points for the Tigers at an average of 9.36. In 1986 Moran was joined by his brother Kelly at Sheffield. Moran also helped the US team to second place in both 19 at the Veterans Memorial Stadium in Long Beach (the only times that the World Team Cup Finals were held outside of Great Britain or Europe), while finishing third in 1984 ( Leszno, Poland) and 1987 (three rounds held at Fredericia in Denmark, Coventry, England and Prague, Czechoslovakia). He would later repeat this success with Team USA in 1990 at the Svítkov Stadion in Pardubice, Czechoslovakia alongside Sam Ermolenko, Rick Miller, Billy Hamill and Kelly Moran. In 1982, along with reigning World Champion Bruce Penhall, Bobby Schwartz, Scott Autrey, and his older brother Kelly Moran, Shawn won the Speedway World Team Cup at the White City Stadium in London, England. Shawn and fellow Californian Ron Preston who won the title in 1979, are the only American riders to have won the Under-21 title (as of 2014). This championship was renamed as the World Under-21 Championship in 1988. He joined Sheffield from Hull in 1980 for £8,000 and established himself as a fans' favourite who topped the clubs averages every year he was with them.Īfter finishing 15th at the 1980 European Under-21 Championship, Moran won the 1981 Championship in Slaný, Czechoslovakia with a 15-point maximum. Moran first rode in British speedway for Hull Vikings in 1979 under the alias 'David East', before riding under his real identity in 1980. ![]() ).Shawn Moran (born Novemin Lakewood, California) is an American former professional motorcycle speedway rider who was one of the most popular and talented riders ever to race for Sheffield Tigers who also represented the United States in international speedway competitions. ![]() (Funded by Amarin Pharma REDUCE-IT number, NCT01492361. Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06).Īmong patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75 95% confidence interval, 0.68 to 0.83 P<0.001) the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74 95% CI, 0.65 to 0.83 P<0.001). The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.Ī total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. Patients with elevated triglyceride levels are at increased risk for ischemic events.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |